Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Associated Therapies: -

Clinical Trials

Antibiotics Continuous Infusion at Home

Phase 1

Conditions: Severe Bacterial Infections

Interventions: Drug: Piperacillin/tazobactam
Drug: Cefepime
Drug: Meropenem
Drug: Vancomycin

First Posted Date: 2021-03-25

Last Posted Date: 2021-03-25

Lead Sponsor: Ospedale San Carlo Borromeo

Target Recruit Count: 50

Registration Number: NCT04816968

Locations: 🇮🇹
ASST Santi Paolo Carlo - San Carlo Borromeo Hospital - SSd Onco-Hematology, Milan, Italy

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Phase 3

Terminated

Conditions: Clostridioides Difficile Infection

Interventions: Drug: Ridinilazole
Drug: Vancomycin

First Posted Date: 2021-03-17

Last Posted Date: 2023-08-21

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 2

Registration Number: NCT04802837

Locations: 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇺🇸
Continental Clinical Research, Miami, Florida, United States
🇺🇸
Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States

and more 15 locations

Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC

Not Applicable

Recruiting

Conditions: MRSA

Interventions: Drug: Vancomycin

First Posted Date: 2021-03-11

Last Posted Date: 2024-11-25

Lead Sponsor: McMaster University

Target Recruit Count: 700

Registration Number: NCT04793152

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Phase 2

Completed

Conditions: Staphylococcal Bacteraemia

Interventions: Drug: Dalbavancin
Drug: Cefazolin
Drug: Daptomycin
Drug: Nafcillin
Drug: Oxacillin
Drug: Vancomycin

First Posted Date: 2021-03-01

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT04775953

Locations: 🇺🇸
Corewell Health - Infectious Disease, Royal Oak, Michigan, United States
🇺🇸
University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸
University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States

and more 21 locations

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Phase 2

Active, not recruiting

Conditions: Metastatic Small Intestinal Adenocarcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IV Small Intestinal Adenocarcinoma AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Metastatic Colorectal Adenocarcinoma
Stage IVC Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Fecal Microbiota Transplantation
Drug: Fecal Microbiota Transplantation Capsule
Drug: Metronidazole
Drug: Neomycin
Biological: Nivolumab
Biological: Pembrolizumab
Other: Questionnaire Administration
Drug: Vancomycin

First Posted Date: 2021-01-28

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04729322

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

Phase 1

Completed

Conditions: Hand Injuries
Hand Injuries and Disorders
Infection
Hand Injury Wrist
Hand Arthritis

Interventions: Procedure: Bier Block
Drug: Systemic IV Vancomycin
Drug: Vancomycin

First Posted Date: 2020-12-17

Last Posted Date: 2022-10-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT04673877

Locations: 🇺🇸
Mayo Clinic in Arizona, Phoenix, Arizona, United States

Precision Dosing of Vancomycin in Critically Ill Children

Phase 4

Active, not recruiting

Conditions: Vancomycin

Interventions: Device: vancomycin model-informed precision dosing
Drug: Vancomycin

First Posted Date: 2020-12-14

Last Posted Date: 2024-04-12

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 314

Registration Number: NCT04666948

Locations: 🇧🇪
AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium
🇧🇪
Cliniques universitaires de Saint Luc, Brussels, Belgium
🇧🇪
Ghent University Hospital, Ghent, Belgium

and more 4 locations

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Phase 2

Completed

Conditions: Clostridium Difficile Infection

Interventions: Drug: Ibezapolstat
Drug: Vancomycin

First Posted Date: 2020-01-30

Last Posted Date: 2024-05-14

Lead Sponsor: Acurx Pharmaceuticals Inc.

Target Recruit Count: 32

Registration Number: NCT04247542

Locations: 🇺🇸
Acurx Site #103: Dr John Pullman, Butte, Montana, United States
🇺🇸
Acurx Site #114: Dr Eugene Ryan, Chattanooga, Tennessee, United States
🇺🇸
Acurx Site #121: Dr Ramesh Gowrappala, Houston, Texas, United States

and more 26 locations

Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients

Early Phase 1

Recruiting

Conditions: Clostridium Difficile Colonization
Clostridium Difficile Diarrhea

Interventions: Dietary Supplement: Culturelle
Drug: Vancomycin
Drug: Probiotic Placebo
Drug: Vancomycin Placebo

First Posted Date: 2020-01-29

Last Posted Date: 2023-09-21

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 100

Registration Number: NCT04246151

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

Phase 3

Active, not recruiting

Conditions: Clostridium Difficile Infection

Interventions: Drug: Placebos
Drug: Vancomycin

First Posted Date: 2019-10-24

Last Posted Date: 2024-08-09

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 263

Registration Number: NCT04138706

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦
Sunnybrook Health Science Centre, Toronto, Ontario, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy